Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13363241 | 0.89 | NR4A2 (0.58) | HDAC1HDAC2HDAC3NR4A2KDM4E | |
| SCHEMBL20235825 | 0.84 | NR4A2 (0.60) | HDAC1HDAC2HDAC3NR4A2KDM4E | |
| SCHEMBL4685813 | 0.83 | NR4A2 (0.62) | NR4A2KDM4E | |
| SCHEMBL3561581 | 0.82 | KCNH2 (0.62) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL7529190 | 0.81 | KDM4E (0.66) | KDM4ENPC1MAPT | |
| SCHEMBL3348427 | 0.80 | NR4A2 (0.58) | HDAC1HDAC2HDAC3NR4A2KDM4E | |
| SCHEMBL23791804 | 0.80 | NEK2 (0.57) | HDAC1HDAC2HDAC3NR4A2KDM4E | |
| SCHEMBL31437927 | 0.80 | NEK2 (0.57) | HDAC1HDAC2HDAC3NR4A2KDM4E | |
| SCHEMBL1308179 | 0.78 | TUBB4A (0.67) | — | |
| SCHEMBL30118381 | 0.78 | HDAC1 (0.77) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| CN-111247143-B | Pyridoquinazoline derivatives useful as inhibitors of protein kinases | 昂科斯特拉公司 | 2022-07-05 | — | — | CN | disclosed |
| US-11021479-B2 | Pyridoquinazoline derivatives useful as protein kinase inhibitors | ONCOSTELLAE, S.L. (ES) | 2021-06-01 | — | — | US | disclosed |
| US-11021479-B2 | Pyridoquinazoline derivatives useful as protein kinase inhibitors | ONCOSTELLAE, S.L. (ES) | 2021-06-01 | — | — | US | disclosed |
| EP-3632912-B1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | ONCOSTELLAE S L (ES) | 2021-03-17 | — | — | EP | disclosed |
| EP-3632912-B1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | ONCOSTELLAE S L (ES) | 2021-03-17 | — | — | EP | disclosed |
| CN-111247143-A | Pyridoquinazoline derivatives useful as inhibitors of protein kinases | 昂科斯特拉公司 | 2020-06-05 | — | — | CN | disclosed |
| US-20200148676-A1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | ONCOSTELLAE, S.L. (ES) | 2020-05-14 | — | — | US | disclosed |
| US-20200148676-A1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | ONCOSTELLAE, S.L. (ES) | 2020-05-14 | — | — | US | disclosed |
| EP-3632913-A1 | CARBOXYLIC ACID DERIVATIVES OF PYRIDOQUINAZOLINES USEFUL AS PROTEIN KINASE INHIBITORS | Oncostellae, S.L. (ES) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632912-A1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | Oncostellae, S.L. (ES) | 2020-04-08 | — | — | EP | disclosed |
| US-20200079773-A1 | CARBOXYLIC ACID DERIVATIVES OF PYRIDOQUINAZOLINES USEFUL AS PROTEIN KINASE INHIBITORS | ONCOSTELLAE, S.L. (ES) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148676-A1 | PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP4K2, MAP4K1, MAP4K3 | HDAC1 1179/4885HDAC2 1415/4885HDAC3 1647/4885 |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | HDAC1 1462/4885HDAC2 1558/4885HDAC3 1946/4885 |
| US-20200079773-A1 | CARBOXYLIC ACID DERIVATIVES OF PYRIDOQUINAZOLINES USEFUL AS PROTEIN KINASE INHIBITORS | MAP4K2, MAP3K1, MAP4K1 | HDAC1 718/4885HDAC2 1077/4885HDAC3 783/4885 |
| US-11021479-B2 | Pyridoquinazoline derivatives useful as protein kinase inhibitors | MAP4K2, MAP4K1, MAP4K3 | HDAC1 1179/4885HDAC2 1415/4885HDAC3 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.